Last reviewed: June 21, 2026
Last updated: June 21, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) was approved by the FDA in 2017 specifically for type 2 diabetes management, with a focus on lowering blood glucose levels and reducing cardiovascular risk. While clinical trials documented significant weight loss as a side effect, the medication was never developed or labeled as a weight-loss drug. Today, millions seek semaglutide for weight management, often facing supply constraints and high out-of-pocket costs.
The Original Purpose of Ozempic in Diabetes Treatment
Ozempic entered the market as a once-weekly injectable GLP-1 receptor agonist designed to help adults with type 2 diabetes achieve better blood sugar control. The drug mimics glucagon-like peptide-1, a hormone that signals the pancreas to release insulin when blood glucose rises. In clinical trials, patients taking semaglutide showed an average HbA1c reduction of 1.5 percent, a meaningful improvement in long-term glucose management. The FDA labeled Ozempic for diabetes because that was its primary clinical indication and the focus of its development studies.
Beyond blood sugar control, Ozempic demonstrated cardiovascular benefits in the SUSTAIN-6 trial, reducing heart attacks and strokes in diabetic patients with existing heart disease. This cardiovascular protection became a key reason physicians prescribed the medication to eligible diabetes patients. The weight loss observed in these trials was documented but considered a secondary benefit, not the primary therapeutic goal. Insurance companies therefore covered Ozempic mainly for diabetes, with weight loss off-label coverage varying by plan.
How Semaglutide Causes Weight Loss When Used Off-Label
Although Ozempic was not developed as a weight-loss drug, semaglutide reduces appetite and body weight through its action on GLP-1 receptors in the brain and gut. When the drug binds to these receptors, it slows gastric emptying, increases feelings of fullness, and reduces hunger signals sent to the hypothalamus. These mechanisms mean that people taking semaglutide eat less without conscious effort, leading to calorie deficit and weight loss. The appetite suppression occurs independently of the blood sugar-lowering effect, which explains why the drug works for weight loss in people without diabetes.
Clinical data shows that semaglutide produces weight loss in a dose-dependent manner, with higher doses generally producing greater reductions in body weight. In the STEP trials, which tested semaglutide specifically for chronic weight management in non-diabetic adults, participants lost an average of 15 percent of their starting body weight over 68 weeks. This weight loss occurred because the medication changed how the brain and gut communicate about hunger and satiety, not because it treated an underlying metabolic disease in non-diabetic users.
Why Ozempic Supply Is Limited and Costs Are High
Ozempic supply constraints emerged after semaglutide became a popular weight-loss choice, even though the medication was manufactured only for diabetes indication. Novo Nordisk, the pharmaceutical manufacturer, could not instantly scale production to meet off-label demand, leading to widespread shortages and back-orders. These supply issues made it difficult for people with diabetes to access their prescribed medication, forcing some to switch to alternative diabetes drugs or face treatment gaps. The shortage situation improved over time but highlighted the tension between primary indication availability and off-label demand.
Brand-name Ozempic typically costs $800 to $1,200 per month without insurance, placing it out of reach for most people seeking weight loss. Insurance rarely covers the medication for weight management, only for diabetes, meaning patients must pay full price or find alternatives. PlexusDx offers compounded semaglutide injection starting at $149 per month, a fraction of brand-name cost, with no insurance required and HSA/FSA eligibility. This pricing structure makes semaglutide therapy accessible to people who could not afford Ozempic brand name.
Compounded Semaglutide as a Clinical Alternative to Ozempic
Compounded semaglutide from licensed 503A pharmacies offers the same active ingredient as Ozempic but at significantly lower cost and with greater availability. The FDA permits licensed compounding pharmacies to prepare semaglutide injections when brand-name supplies are constrained or when patients require customized dosing. PlexusDx partners with 503A facilities to compound semaglutide safely and reliably, with each batch tested for sterility and potency before dispensing. Patients receive the same GLP-1 agonist mechanism as Ozempic, supporting both weight loss and metabolic health in those who qualify.
PlexusDx also offers oral semaglutide and the Precision Peptide Genetic Test to identify which patients are most likely to respond well to semaglutide therapy. The genetic test examines variants in GLP1R, FTO, GIPR, and MC4R genes that influence peptide hormone sensitivity and weight regulation. By mapping 14 metabolic pathways and 150+ genetic insights, PlexusDx helps clinicians personalize semaglutide dosing and identify patients who may benefit from dual-compound therapies. This precision approach maximizes efficacy while minimizing unnecessary medication use in those unlikely to respond.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic FDA-approved for weight loss?
No. Ozempic is FDA-approved only for type 2 diabetes. A different semaglutide product called Wegovy is FDA-approved for chronic weight management, but Ozempic itself was never labeled for weight loss. Many physicians prescribe Ozempic off-label for weight management because the drug produces weight loss as a side effect, but this use is outside its approved indication.
How much weight do people lose on semaglutide?
In the STEP clinical trials, adults without diabetes lost an average of 15 percent of their starting body weight over 68 weeks on semaglutide. Results vary widely based on dose, genetics, adherence, and lifestyle factors. PlexusDx's Precision Peptide Genetic Test can help predict individual response likelihood by analyzing GLP1R, FTO, and other weight-regulation genes.
Why is Ozempic so expensive compared to PlexusDx compounded semaglutide?
Brand-name Ozempic costs $800–$1,200 monthly because manufacturers set premium prices, and insurance rarely covers it for weight loss. PlexusDx compounded semaglutide injection starts at $149 per month from licensed 503A pharmacies, requiring no insurance and remaining eligible for HSA/FSA accounts. The lower cost reflects compounding efficiency and direct-to-patient pricing without insurance intermediaries.
Are compounded medications from PlexusDx safe?
Yes. PlexusDx sources all compounded medications from licensed 503A compounding pharmacies, which operate under strict FDA oversight and state pharmacy board regulations. Each batch is tested for sterility, potency, and purity before dispensing. Licensed 503A facilities differ from unregulated 503B outsourcing facilities and maintain quality standards comparable to brand-name pharmaceutical preparation.
Can the Precision Peptide Genetic Test predict my weight loss success?
The PlexusDx Precision Peptide Genetic Test ($99 add-on after first month) examines variants in GLP1R, FTO, GIPR, and MC4R genes that influence hunger regulation and metabolic response to semaglutide. Specific genetic profiles correlate with stronger appetite suppression and greater weight loss potential. While genetics is one factor, combined with diet, activity, and medication adherence, the test helps personalize your treatment approach and predict likelihood of response.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Does Wegovy Make You Nauseous When You Eat? Tips for Managing Your Weight Loss Journey
What Percentage of People Gain Weight Back After Mounjaro?